Fennec Pharmaceuticals Inc. (FENC)
Stock Price:
$8.45 USD
0.12 (1.44%)
Updated Jul 31, 2020 4:00 PM EDT - Market closed
Pre-market: $8.89 +0.44 (5.21%) Aug 3, 8:09 AM
Key Info
| Market Cap |
214.26M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-13.98M |
| Shares Out |
25.36M |
| EPS (ttm) |
-0.70 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 31, 2020 |
| Last Price |
$8.45 |
| Previous Close |
$8.33 |
| Change ($) |
0.12 |
| Change (%) |
1.44% |
| Day's Open |
- |
| Day's Range |
8.28 - 8.68 |
| Day's Volume |
345,362 |
| 52-Week Range |
3.91 - 9.75 |
More Stats
| Market Cap |
214.26M |
| Enterprise Value |
204.36M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
25.36M |
| Float |
19.54M |
| EPS (basic) |
-0.7 |
| EPS (diluted) |
-0.70 |
| FCF / Share |
-0.52 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.36M |
| Short Ratio |
3.02 |
| Short % of Float |
7.09% |
| Beta |
0.25 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
24.96 |
| Revenue |
n/a |
| Operating Income |
-14.16M |
| Net Income |
-13.98M |
| Free Cash Flow |
-10.33M |
| Net Cash |
9.90M |
| Net Cash / Share |
0.39 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-57.07% |
| ROE |
-101.02% |
| ROIC |
1,254.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$17.00*
(101.18% upside)
Low
15.0
Current: $8.45
High
18.0
Target: 17.00
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -13.01 | -10.41 | -6.95 | -2.87 | -1.89 | -2.88 | -1.93 | -3.62 | -3.44 | -4.60 |
| Net Income | -12.78 | -9.89 | -7.05 | -2.79 | -0.66 | -2.18 | 1.85 | -5.16 | 4.69 | -7.82 |
| Shares Outstanding | 19.90 | 18.94 | 15.01 | 12.77 | 10.83 | 9.87 | 9.72 | 8.39 | 7.99 | 5.34 |
| Earnings Per Share | -0.64 | -0.52 | -0.47 | -0.22 | -0.06 | -0.22 | 0.17 | -0.63 | 0.57 | -1.47 |
| Operating Cash Flow | -9.06 | -7.83 | -3.64 | -2.12 | -1.86 | -1.70 | -2.21 | -2.99 | -3.23 | -1.93 |
| Free Cash Flow | -9.06 | -7.83 | -3.64 | -2.12 | -1.86 | -1.70 | -2.21 | -2.99 | -3.23 | -1.93 |
| Cash & Equivalents | 13.65 | 22.78 | 28.26 | 3.93 | 0.94 | 2.31 | 1.66 | 2.30 | 5.30 | 5.95 |
| Total Debt | - | - | 0.17 | 0.03 | 0.08 | 1.32 | 2.86 | - | - | - |
| Net Cash / Debt | 13.65 | 22.78 | 28.09 | 3.89 | 0.86 | 0.99 | -1.20 | 2.30 | 5.30 | 5.95 |
| Assets | 14.15 | 22.95 | 28.40 | 3.97 | 1.02 | 2.37 | 1.75 | 2.37 | 5.35 | 5.99 |
| Liabilities | 2.27 | 1.64 | 1.64 | 0.40 | 0.47 | 1.76 | 3.21 | 7.32 | 5.47 | 10.92 |
| Book Value | 11.88 | 21.31 | 26.76 | 3.57 | 0.55 | 0.61 | -1.46 | -4.96 | -0.12 | -4.92 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Fennec Pharmaceuticals Inc. |
| Country |
United States |
| Employees |
5 |
| CEO |
Rostislav C. Raykov |
Stock Information
| Ticker Symbol |
FENC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: FENC |
| IPO Date |
June 5, 2001 |
Description
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.